Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Clinical trial NCT05573126 · RECRUITING

Trial details

NCT number: NCT05573126
Sponsor: Ellipses Pharma
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Hormone Receptor-positive Breast Cancer Hormone Receptor Positive HER-2 Negative Breast Cancer Metastatic Breast Cancer

Start date: 2023-01-11
Primary completion: 2028-02-01
Enrollment: 95

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.